Logo

Ciphergen s Revenues Down, Losses Narrowed During Q2

Jul 30, 2004

NEW YORK, July 30 (GenomeWeb News) - Ciphergen Biosystems yesterday reported sliding revenues and narrowed losses for the second quarter.

 

The company booked $10.8 million in revenues for the quarter, down from $14.3 million during the same quarter in 2003.

 

R&D costs decreased to $6 million, from $7 million during the same quarter last year.

 

The company's net loss amounted to $13.1 million, down from $15.6 million during the second quarter a year ago. Last year's net loss included a $7.3 million non-recurring litigation settlement.

 

As of June 30, Ciphergen had $29.8 million in cash, cash equivalents and investments in securities.

Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.